{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:19:31Z","timestamp":1768781971257,"version":"3.49.0"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100002708","name":"Agence Universitaire de la Francophone","doi-asserted-by":"publisher","award":["AUF- 463\/2020"],"award-info":[{"award-number":["AUF- 463\/2020"]}],"id":[{"id":"10.13039\/501100002708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Coronavirus Disease 2019 (COVID-19) pandemic continues to threaten patients, societies and healthcare systems around the world. There is an urgent need to search for possible medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This article intends to use virtual screening and molecular docking methods to find potential inhibitors from existing drugs that can respond to COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>To take part in the current research investigation and to define a potential target drug that may protect the world from the pandemic of corona disease, a virtual screening study of 129 approved drugs was carried out which showed that their metabolic characteristics, dosages used, potential efficacy and side effects are clear as they have been approved for treating existing infections. Especially 12 drugs against chronic hepatitis B virus, 37 against chronic hepatitis C virus, 37 against human immunodeficiency virus, 14 anti-herpesvirus, 11 anti-influenza, and 18 other drugs currently on the market were considered for this study. These drugs were then evaluated using virtual screening and molecular docking studies on the active site of the (SARS-CoV-2) main protease (6lu7). Once the efficacy of the drug is determined, it can be approved for its in vitro and in vivo activity against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which can be beneficial for the rapid clinical treatment of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>These drugs were considered potentially effective against SARS-CoV-2 and those with high molecular docking scores were proposed as novel candidates for repurposing. The N3 inhibitor cocrystallized with protease (6lu7) and the anti-HIV protease inhibitor Lopinavir were used as standards for comparison.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The results suggest the effectiveness of Beclabuvir, Nilotinib, Tirilazad, Trametinib and Glecaprevir as potent drugs against SARS-CoV-2 since they tightly bind to its main protease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>These promising drugs can inhibit the replication of the virus; hence, the repurposing of these compounds is suggested for the treatment of COVID-19. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. However, the assessment of these potential inhibitors as clinical drugs requires further in vivo tests of these drugs.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1386207323999200730205447","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T10:17:16Z","timestamp":1596622636000},"page":"441-454","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening"],"prefix":"10.2174","volume":"24","author":[{"given":"Samir","family":"Chtita","sequence":"first","affiliation":[{"name":"Laboratory of Physical Chemistry of Materials, Faculty of sciences Ben M\u2019Sik, Hassan II University of Casablanca, B.P. 7955 Sidi Othmane, Casablanca,Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Belhassan","sequence":"additional","affiliation":[{"name":"Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University, B.P. 11201 Zitoune, Meknes,Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnane","family":"Aouidate","sequence":"additional","affiliation":[{"name":"Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University, B.P. 11201 Zitoune, Meknes,Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Belaidi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Chemistry and Environment, Group of Computational and pharmaceutical Chemistry, University of Biskra, BP145, 07000, Biskra,Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Bouachrine","sequence":"additional","affiliation":[{"name":"High School of Technology of Khenifra, Sultan Slimane University, B.P. 591, Khenifra,Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Lakhlifi","sequence":"additional","affiliation":[{"name":"Molecular Chemistry and Natural Substances Laboratory, Faculty of Science, Moulay Ismail University, B.P. 11201 Zitoune, Meknes,Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","volume":"76","author":"Sohrabi C.","year":"2020","unstructured":"Sohrabi C.; Alsafi Z.; O\u2019Neill N.; Khan M.; Kerwan A.; Al-Jabir A.; Iosifidis C.; Agha R.; World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020,76,71-76","journal-title":"Int J Surg"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"Fehr A.R.","year":"2015","unstructured":"Fehr A.R.; Perlman S.; Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015,1282,1-23","journal-title":"Methods Mol Biol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"Li F.","year":"2016","unstructured":"Li F.; Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016,3(1),237-261","journal-title":"Annu Rev Virol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"Chan J.F.","year":"2020","unstructured":"Chan J.F.; Yuan S.; Kok K.H.; To K.K.; Chu H.; Yang J.; Xing F.; Liu J.; Yip C.C.; Poon R.W.S.; Tsoi H.W.; Lo S.K.F.; Chan K.H.; Poon V.K.M.; Chan W.M.; Ip J.D.; Cai J-P.; Cheng V.C.; Chen H.; Hui C.K.; Yuen K.Y.; A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020,395(10223),514-523","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3201\/eid2606.200287","volume":"26","author":"Li Y.","year":"2020","unstructured":"Li Y.; Zhao R.; Zheng S.; Chen X.; Wang J.; Sheng X.; Zhou J.; Cai H.; Fang Q.; Yu F.; Fan J.; Xu K.; Chen Y.; Sheng J.; Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerg Infect Dis 2020,26(6),1335-1336","journal-title":"Emerg Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-8955-3_5","volume":"1903","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Yella J.; Jegga A.G.; Transcriptomic Data Mining and Repurposing for Computational Drug Discovery. Methods Mol Biol 2019,1903,73-95","journal-title":"Methods Mol Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-4939-8955-3_9","volume":"1903","author":"Karatzas E.","year":"2019","unstructured":"Karatzas E.; Kolios G.; Spyrou G.M.; An Application of Computational Drug Repurposing Based on Transcriptomic Signatures. Methods Mol Biol 2019,1903,149-177","journal-title":"Methods Mol Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1089\/omi.2017.0127","volume":"21","author":"Turanli B.","year":"2017","unstructured":"Turanli B.; Gulfidan G.; Arga K.Y.; Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma. OMICS 2017,21(10),584-591","journal-title":"OMICS"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2174\/1386207321666171221112835","volume":"20","author":"Huang G.","year":"2017","unstructured":"Huang G.; Li J.; Wang P.; Li W.; A Review of Computational Drug Repositioning Approaches. Comb Chem High Throughput Screen 2017,20(10),831-838","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1109\/TCBB.2018.2832078","volume":"16","author":"Luo H.","year":"2019","unstructured":"Luo H.; Wang J.; Li M.; Luo J.; Ni P.; Zhao K.; Wu F.X.; Pan Y.; Computational Drug Repositioning with Random Walk on a Heterogeneous Network. IEEE\/ACM Trans Comput Biol Bioinformatics 2019,16(6),1890-1900","journal-title":"IEEE\/ACM Trans Comput Biol Bioinformatics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1039\/c3mb25382a","volume":"9","author":"Wu Z.","year":"2013","unstructured":"Wu Z.; Wang Y.; Chen L.; Network-based drug repositioning. Mol Biosyst 2013,9(6),1268-1281","journal-title":"Mol Biosyst"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.2013.1","volume":"93","author":"Hurle M.R.","year":"2013","unstructured":"Hurle M.R.; Yang L.; Xie Q.; Rajpal D.K.; Sanseau P.; Agarwal P.; Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013,93(4),335-341","journal-title":"Clin Pharmacol Ther"},{"key":"ref=14","author":"FDA Approved Drug Products","unstructured":"FDA Approved Drug Products; Kaletra (lopinavir\/ritonavir) for oral use"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H.; Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"Harrison C.","year":"2020","unstructured":"Harrison C.; Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020,38(4),379-381","journal-title":"Nat Biotechnol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jmv.25783","volume":"92","author":"Wan S.","year":"2020","unstructured":"Wan S.; Xiang Y.; Fang W.; Zheng Y.; Li B.; Hu Y.; Lang C.; Huang D.; Sun Q.; Xiong Y.; Huang X.; Lv J.; Luo Y.; Shen L.; Yang H.; Huang G.; Yang R.; Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020,92(7),797-806","journal-title":"J Med Virol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"Cao B.","year":"2020","unstructured":"Cao B.; Wang Y.; Wen D.; Liu W.; Wang J.; Fan G.; A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. New England J Med 2020,382(19),1787-1799","journal-title":"New England J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/jama.2020.4742","volume":"323","author":"Kalil A.C.","year":"2020","unstructured":"Kalil A.C.; Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020,323(19),1897-1898","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3389\/fphar.2019.01472","volume":"10","author":"Su B.","year":"2019","unstructured":"Su B.; Wang Y.; Zhou R.; Jiang T.; Zhang H.; Li Z.; Liu A.; Shao Y.; Hua W.; Zhang T.; Wu H.; He S.; Dai L.; Sun L.; Efficacy and tolerability of lopinavir\/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol 2019,10(1472),1472","journal-title":"Front Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1752802","author":"Muralidharan N.","year":"2020","unstructured":"Muralidharan N.; Sakthivel R.; Velmurugan D.; Gromiha M.M.; Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn 2020,1-6","journal-title":"J Biomol Struct Dyn"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2020030226","DOI":"10.20944\/preprints202003.0226.v1","author":"Khaerunnisa S.","year":"2020","unstructured":"Khaerunnisa S.; Kurniawan H.; Awaluddin R.; Suhartati S.; Soetjipto S.; Potential Inhibitor of COVID-19 Main Protease (Mpro) 2020,2020030226","journal-title":"Potential Inhibitor of COVID-19 Main Protease (Mpro)"},{"key":"ref=23","author":"G\u00e9rard A.","year":"2020","unstructured":"G\u00e9rard A.; Romani S.; Fresse A.; Viard D.; Parassol N.; Granvuillemin A.; Chouchana L.; Rochera F.; Drici M-D.; \u2018Off-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactionsby the French Network of Pharmacovigilance 2020","journal-title":"\u2018Off-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactionsby the French Network of Pharmacovigilance"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e79","volume":"35","author":"Lim J.","year":"2020","unstructured":"Lim J.; Jeon S.; Shin H-Y.; Kim M.J.; Seong Y.M.; Lee W.J.; Choe K-W.; Kang Y.M.; Lee B.; Park S-J.; Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020,35(6)","journal-title":"J Korean Med Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","volume":"47","author":"Liu X.","year":"2020","unstructured":"Liu X.; Wang X.J.; Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics 2020,47(2),119-121","journal-title":"J Genet Genomics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jtbi.2008.07.030","volume":"254","author":"Nukoolkarn V.","year":"2008","unstructured":"Nukoolkarn V.; Lee V.S.; Malaisree M.; Aruksakulwong O.; Hannongbua S.; Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol 2008,254(4),861-867","journal-title":"J Theor Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.chempr.2020.04.023","volume":"6","author":"D\u00f6mling A.","year":"2020","unstructured":"D\u00f6mling A.; Gao L.; Chemistry and Biology of SARS-CoV-2. Chem 2020,6(6),1283-1295","journal-title":"Chem"},{"key":"ref=28","author":"Liu X.","year":"2020","unstructured":"Liu X.; Zhang B.; Jin Z.; Yang H.; Rao Z.; The crystal structure of COVID-19 main protease in complex with an inhibitor N3 Complex (PDB ID: 6lu7) 2020"},{"key":"ref=29","author":"Dassault Syst\u00e8mes B.I.O.V.I.A.","year":"2016","unstructured":"Dassault Syst\u00e8mes B.I.O.V.I.A.; Discovery Studio Modeling Environment, Release 2017 2016","journal-title":"Discovery Studio Modeling Environment, Release 2017"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=31","first-page":"26","volume":"6","author":"Saxena S.K.","year":"2010","unstructured":"Saxena S.K.; Saxena S.; Saxena R.; Swamy A.; Gupta A.; Nai M.; Emerging Trends, Challenges and Prospects in Antiviral Therapeutics and Drug Development for Infectious Diseases, Electronic. J Biol 2010,6(2),26-31","journal-title":"J Biol"},{"key":"ref=32","unstructured":"Sybyl-X 2.0 Tripos International, St. Louis, Missouri, 63144, USA"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461 https:\/\/10.1002%2Fjcc.21334","journal-title":"J Comput Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/ijms17020144","volume":"17","author":"Du X.","year":"2016","unstructured":"Du X.; Li Y.; Xia Y-L.; Ai S-M.; Liang J.; Sang P.; Ji X-L.; Liu S-Q.; Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods. Int J Mol Sci 2016,17(2),144","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00283","author":"Hatada R.","year":"2020","unstructured":"Hatada R.; Okuwaki K.; Mochizuki Y.; Handa Y.; Fukuzawa K.; Komeiji Y.; Okiyama Y.; Tanaka S.; Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7). J Chem Inf Model 2020","journal-title":"J Chem Inf Model"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jvh.12372","volume":"22","author":"Tatum H.","year":"2015","unstructured":"Tatum H.; Thuluvath P.J.; Lawitz E.; Martorell C.; DeMicco M.; Cohen S.; Rustgi V.; Ravendhran N.; Ghalib R.; Hanson J.; Zamparo J.; Zhao J.; Cooney E.; Treitel M.; Hughes E.; A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1. J Viral Hepat 2015,22(8),658-664","journal-title":"J Viral Hepat"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.clml.2019.12.001","volume":"20","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Yin H.; Chen L.; Xiong Y.; Meng L.; Guo J.; Wang H.; Li W.; Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2020,20(2),e43-e49","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/01.STR.25.2.418","volume":"25","year":"1994","unstructured":"Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke STIPAS Investigators1994,25(2),418-423","journal-title":"Stroke"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101907","author":"Lian T.","year":"2019","unstructured":"Lian T.; Li C.; Wang H.; Trametinib in the treatment of multiple malignancies harboring MEK1 mutations. Cancer Treat Rev 2019","journal-title":"Cancer Treat Rev"},{"key":"ref=40","first-page":"503","year":"2017","unstructured":"Recommended International Nonproprietary Names: List 76 International Nonproprietary Names for Pharmaceutical Substances2017,503","journal-title":"Recommended International Nonproprietary Names: List 76"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184406\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T10:05:19Z","timestamp":1723370719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184406\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323999200730205447","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}